Targeting the EGF receptor ectodomain in the context of cancer

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Expert opinion on therapeutic targets

• Publication date

  2009-10-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1517/14728220903277264PMID 19769546
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cost Considerations in the Treatment of Colorectal Cancer

  2012cited by this paper
• National Institute for Health and Clinical Excellence

  2010cited by this paper
• Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

  2009cited by this paper
• The EGFRvIII variant in glioblastoma multiforme.

  2009cited by this paper
• General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold*

  2009cited by this paper
• The ErbB kinase domain: structural perspectives into kinase activation and inhibition.

  2009cited by this paper
• Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation.

  2009cited by this paper
• Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology

  2008cited by this paper
• Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.

  2008cited by this paper
• Survival of cancer cells is maintained by EGFR independent of its kinase activity.

  2008cited by this paper
• Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab

  2008influential reference
• Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs

  2008cited by this paper
• Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

  2008cited by this paper
• Comparison of the Biodistribution and Tumor Targeting of Two 99mTc-Labeled Anti-EGFR Nanobodies in Mice, Using Pinhole SPECT/Micro-CT

  2008cited by this paper
• SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression

  2008cited by this paper
• The status and role of ErbB receptors in human cancer.

  2008cited by this paper
• Origins of Growth Factors: NGF and EGF

  2008cited by this paper
• Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer.

  2008cited by this paper
• Single-molecule imaging and fluorescence lifetime imaging microscopy show different structures for high- and low-affinity epidermal growth factor receptors in A431 cells.

  2008cited by this paper
• Effector mechanisms of therapeutic antibodies against ErbB receptors.

  2008cited by this paper
• Correlation between NK function and response to trastuzumab in metastatic breast cancer patients

  2008cited by this paper
• Studies on anticancer activities of antimicrobial peptides.

  2008cited by this paper
• Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor.

  2008cited by this paper
• The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility

  2008cited by this paper
• Oncogenes and cancer.

  2008cited by this paper
• Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.

  2008cited by this paper
• Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528.

  2008cited by this paper
• Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3

  2007cited by this paper
• Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines

  2007cited by this paper
• Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer

  2007cited by this paper
• Selection and characterization of an internalizing epidermal‐growth‐factor‐receptor antibody

  2007cited by this paper
• Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.

  2007cited by this paper
• Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor

  2007cited by this paper
• Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII.

  2007cited by this paper
• Nuclear factor-κB activation: a molecular therapeutic target for estrogen receptor–negative and epidermal growth factor receptor family receptor–positive human breast cancer

  2007cited by this paper
• Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial

  2007cited by this paper
• Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: An updated analysis

  2007influential reference
• A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors

  2007cited by this paper
• Correlation between NK function and response to trastuzumab in metastatic breast cancer

  2007cited by this paper
• Panitumumab a novel drug in cancer treatment.

  2007cited by this paper
• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007influential reference
• Mechanisms for oncogenic activation of the epidermal growth factor receptor.

  2007cited by this paper
• Epidermal Growth Factor Receptor-Targeted Therapy for Pancreatic Cancer

  2007cited by this paper
• Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies

  2007cited by this paper
• Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy

  2007cited by this paper
• A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies.

  2007cited by this paper
• Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors.

  2007cited by this paper
• Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer.

  2007cited by this paper
• Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor.

  2007cited by this paper
• Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting.

  2006influential reference
• Generation of heavy-chain-only antibodies in mice

  2006cited by this paper
• Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.

  2006cited by this paper
• Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor.

  2006cited by this paper
• Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor

  2006cited by this paper
• Heavy-chain-only antibody expression and B-cell development in the mouse.

  2006cited by this paper
• Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis.

  2006cited by this paper
• Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment?

  2006cited by this paper
• An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.

  2006cited by this paper
• Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice

  2006cited by this paper
• A phase I study of IMC-11F8, a fully human anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors. Interim results.

  2006cited by this paper
• Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition

  2006cited by this paper
• Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival

  2006cited by this paper
• Epidermal growth factor receptor (EGFR) signaling in cancer.

  2006cited by this paper
• Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial

  2006cited by this paper
• Suppressors of Cytokine Signaling 4 and 5 Regulate Epidermal Growth Factor Receptor Signaling*

  2005cited by this paper
• GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways

  2005cited by this paper
• Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer.

  2005cited by this paper
• Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.

  2005cited by this paper
• ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors

  2005cited by this paper
• Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods?

  2005cited by this paper
• The antitumor monoclonal antibody 806 recognizes a high‐mannose form of the EGF receptor that reaches the cell surface when cells over‐express the receptor

  2005cited by this paper
• Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

  2005cited by this paper
• epidermal growth factor receptor

  2005cited by this paper
• Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.

  2005cited by this paper
• Biological significance of c-erbB family oncogenes in head and neck cancer

  2005cited by this paper
• Inhibition of signaling from Type 1 receptor tyrosine kinases via intracellular expression of single-chain antibodies

  2005cited by this paper
• Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells.

  2005cited by this paper
• Simultaneous Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling and Enhanced Activation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Receptor-mediated Apoptosis Induction by an scFv:sTRAIL Fusion Protein with Specificity for Human EGFR*

  2005cited by this paper
• Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signaling.

  2005cited by this paper
• ERBB receptors and cancer: the complexity of targeted inhibitors

  2005cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Origins of Growth Factors: NGF and EGF

  2004cited by this paper
• Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody*

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands

  2004cited by this paper
• Targeted gene delivery using humanized single‐chain antibody with negatively charged oligopeptide tail

  2004cited by this paper
• Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Radioimmunoimaging. Advances and prospects.

  2004cited by this paper
• Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

  2004cited by this paper
• Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

  2003cited by this paper
• Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases.

  2003cited by this paper
• The epidermal growth factor receptor pathway and its inhibition as anticancer therapy.

  2003cited by this paper
• Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.

  2003cited by this paper
• EGFRvIII-mediated radioresistance through a strong cytoprotective response

  2003cited by this paper
• Regulation of Receptor Tyrosine Kinase Signaling by Protein Tyrosine Phosphatase-1B*

  2003cited by this paper
• Growth factor receptors in breast cancer: potential for therapeutic intervention.

  2003cited by this paper
• Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer

  2003cited by this paper

• Development of novel high-affinity nanobodies against EGFR for cancer therapy

  2025cites this paper
• EGFR targeted thermosensitive liposomes: A novel multifunctional platform for simultaneous tumor targeted and stimulus responsive drug delivery.

  2016cites this paper